VeriSIM Life
is building "full-stack predictive infrastructure" to help pharma companies foresee translation challenges from laboratory discovery to human therapy, formalizing a research collaboration with the FDA's National Center for Toxicological Research in June 2026 under the agency's Roadmap to Reducing Animal Testing in Prec…
- Country
- United States
FDA NCTR collaboration
us
Coverage
| CN | EU | US | |
|---|---|---|---|
| regenerative-personalized | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Patient digital twins & in-silico trials | regenerative-personalized | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.